Our algorithm follows WHO guidance and CD4 counts are helpful beyond defining eligibility of patients for AHD screening, e.g. to assess the probability of pneumocystis pneumonia in patients with shortness of breath or of toxoplasmosis with focal neurological symptoms. Here, CD4 is linked to mitochondrial DNA depletion syndrome 4a.